Jan P van Meerbeeck
Overview
Explore the profile of Jan P van Meerbeeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
4371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aerts J, Belderbos R, Baas P, Scherpereel A, Bezemer K, Enninga I, et al.
Lancet Oncol
. 2024 Jun;
25(7):865-878.
PMID: 38848742
Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We aimed to establish the efficacy of dendritic cells loaded with allogeneic tumour cell...
2.
Raskin J, Surmont V, Maat A, Yahia M, Burgers S, Pretzenbacher Y, et al.
Eur Respir J
. 2024 Jun;
63(6).
PMID: 38843916
Background: The role of surgery in pleural mesothelioma remains controversial. It may be appropriate in highly selected patients as part of a multimodality treatment including chemotherapy. Recent years have seen...
3.
Walls G, Mistry H, Barlesi F, Bezjak A, Le Pechoux C, OBrien M, et al.
Int J Radiat Oncol Biol Phys
. 2024 Mar;
119(5):1386-1390.
PMID: 38521132
Purpose: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered...
4.
Zwijsen K, Schillebeeckx E, Janssens E, Cleemput J, Richart T, Surmont V, et al.
J Breath Res
. 2023 Sep;
17(4).
PMID: 37683624
Pleural mesothelioma (PM) is an aggressive cancer of the serosal lining of the thoracic cavity, predominantly caused by asbestos exposure. Due to nonspecific symptoms, PM is characterized by an advanced-stage...
5.
Tournoy K, Adam V, Muylle I, De Rijck H, Everaert E, Eqlimi E, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568637
Background: For patients receiving therapy with curative or palliative intent for a thoracic malignancy, prediction of quality of life (QOL), once therapy starts, remains challenging. The role of health assessments...
6.
Raskin J, Van Schil P, van Meerbeeck J
Transl Lung Cancer Res
. 2023 Mar;
12(2):184-186.
PMID: 36895921
No abstract available.
7.
Occhipinti M, Filippi A, Walsh S, van Meerbeeck J
Front Oncol
. 2023 Feb;
12:1116315.
PMID: 36741725
No abstract available.
8.
Diab Garcia P, Snoeckx A, van Meerbeeck J, Van Hal G
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612273
Lung cancer is the most common and deadliest cancer in the world, and its incidence is expected to grow. Nonetheless, this growth can be contained through smoking cessation programs and...
9.
Paternot S, Raspe E, Meiller C, Tarabichi M, Assie J, Libert F, et al.
Mol Oncol
. 2022 Dec;
18(4):866-894.
PMID: 36453028
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines including 19 patient-derived ones,...
10.
Horgan D, Baird A, Middleton M, Mihaylova Z, van Meerbeeck J, Vogel-Claussen J, et al.
Healthcare (Basel)
. 2022 Sep;
10(9).
PMID: 36141230
Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for...